Trial Profile
An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs M 8891 (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute
- 29 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2020 Preliminary results (n=24) of dose escalation part of this trial presented at the 45th European Society for Medical Oncology Congress
- 15 Jul 2020 Planned number of patients changed from 27 to 97.